Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 49 - 56 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC1100 | Enzastaurin (LY317615) |
|
Potent PKC<span class='symbol'>β</span> inhibitor (IC<sub>50</sub> values are 6, 39, 83 and 110 nM for PKC<span class='symbol'>β</span>, PKC<span class='symbol'>α</span>, PKC<span class='symbol'>γ</span> and PKC<span class='symbol'>ε</span>, respectively). Suppresses proliferation and induces apoptosis in HCT116 colon carcinoma and U87MG glioblastoma cells <em>in vitro</em>. Reduces tumor growth and exhibits antiangiogenic activity in HT-29 colon carcinoma xenografts in mice. Also suppresses growth of HCT116 and U87MG xenografts in mice. Orally active.
|
|
| BCC1102 | GW9508 |
|
Potent and selective agonist for the free fatty acid receptor FFA1 (GPR40) (pEC50 values are 7.32, < 4.3 and < 4.3 for FFA1, FFA2 and FFA3 receptors respectively). Inactive against a range of other GPCRs, kinases, proteases, integrins and PPARs. Potentiates glucose-stimulated insulin secretion in MIN6 cells (pEC50 = 6.14).
|
|
| BCC1105 | Roscovitine (Seliciclib,CYC202) |
|
Potent, selective inhibitor of cyclin-dependent kinases (cdk). Inhibits cdc2/cyclin B (IC<sub>50</sub> = 650 nM), cdk2/cyclin A (IC<sub>50</sub> = 700 nM), cdk2/cyclin E (IC<sub>50</sub> = 700 nM), cdk5 / p35 (IC<sub>50</sub> = 160 nM) and is selective over cdk4/cyclin D1 and cdk6/cyclin D3 (IC<sub>50</sub> > 100 <span class='symbol'>μ</span>M). Also selective over a wide range of related kinases including ERK1 and ERK2. Arrests L1210 cells in G<sub>1</sub> phase. Inhibits phosphorylation of vimentin <em>in vivo</em>. Antimitotic.
|
|
| BCC1110 | KU-0060648 |
|
Dual PI 3-K and DNA-PK inhibitor (IC<sub>50</sub> values are <0.1, 0.5, 4 and 19 nM for PI 3-K<span class='symbol'>δ</span>, PI 3-K<span class='symbol'>β</span>, PI 3-K<span class='symbol'>α</span> and DNA-PK respectively). Inhibits proliferation of MCF7 cells <em>in vitro</em> and delays growth of MCF7 xenografts in mice. Also enhances CRISPR-Cas9-mediated homology-directed repair (HDR) efficiency ~2 to 4-fold, and decreases nonhomologous end-joining (NHEJ) frequency ~40%; maximum effect seen at 250 nM.
|
|
| BCC1112 | PD184352 (CI-1040) |
|
Selective MEK inhibitor (K<sub>i</sub> = 300 nM <em>in vitro</em>). Suppresses FGF-mediated angiogenesis <em>in vivo</em> and decreases VEGF expression. Enhances the therapeutic efficacy of taxol <em>in vivo</em>. Orally active.
|
|
| BCC1114 | Mianserin HCl |
|
Non-selective 5-HT<sub>2</sub> receptor antagonist (K<sub>i</sub> values are 0.0080 and 0.0081 <span class='symbol'>μ</span>M for human 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors expressed in HEK293 cells respectively). Has moderate affinity for 5-HT<sub>6</sub>. Antidepressant.
|
|
| BCC1116 | Ki8751 |
|
Potent, selective inhibitor of VEGFR-2 tyrosine kinase (IC<sub>50</sub> = 0.9 nM). Displays some inhibitory activity towards c-Kit, PDGFR<span class='symbol'>α</span> and FGFR-2 (IC<sub>50</sub> values range from 40 to 170 nM) but is highly selective over other receptor tyrosine kinases (IC<sub>50</sub> > 10000 nM for FGFR-2, EGFR and HGFR). Inhibits VEGF-stimulated proliferation of human umbilical vein endothelial cells (HUVEC) and inhibits tumor growth <em>in vivo</em>; antiangiogenic.
|
|
| BCC1117 | Doxorubicin (Adriamycin) HCl |
|
Antitumor antibiotic agent that inhibits DNA topoisomerase II. DNA intercalator that inhibits nucleic acid synthesis and induces apoptosis. Reduces intracellular tau levels.
|
|